Work

1654P TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1735

Authors: J.S. de Bono, C. Helissey, K. Fizazi, J.P. Maroto Rey, G. Roubaud, E.S. Antonarakis, S.K. Sandhu, N.D. Shore, R. Ratta, B. Perez Valderrama, C. Vulsteke, L. Schafer, G. Marr, E. Zhao, A.F. Ward, J.M. Piulats Rodriguez

Institutions: Institute of Cancer Research, Royal Marsden Hospital, Hôpital d'Instruction des Armées Bégin, Institut Gustave Roussy, Hospital de Sant Pau, Institut Bergonié, University of Minnesota, Masonic Cancer Center, Peter MacCallum Cancer Centre, Hôpital Foch, Hospital Universitario Virgen del Rocío, AZ Maria Middelares, MacroGenics (United States), Institut Català d'Oncologia, Duran i Reynals Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4402704906

FWCI: 4.355

Cites:

Cited by: 15

Related to: 10